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Abstract 
The transport characteristics of thyrotropin-releasing hormone (TRH) and its chemically modified derivative with lauric acid 
(Lau-TRH) across the rat small or large intestine were estimated by means of an in vitro everted sac experiment. Both compounds were 
especially absorbed from the upper small intestine. The penetration of TRH across the upper small intestine was significantly increased by 
conjugation with lauric acid. Lau-TRH administered to the mucosal side appeared as a native TRH form in the serosal side. On the other 
hand, a temperature d pendency and a directional difference in the transfer ates of these compounds were observed in the everted and 
non-everted sacs of the upper small intestine. Moreover, the penetration of TRH and Lau-TRH across the upper small intestine was 
inhibited by 0.25 mM 2,4-dinitrophenol and l0 mM glycylglycine. In addition, Lau-TRH was very stable in the cytosolic fraction of the 
small intestinal mucosa, while it was gradually converted to the native TRH in the brush-border membrane (BBM) fraction. The binding 
amounts of TRH to the BBM were remarkably enhanced by the lauric acid conjugation; however, its binding was nonspecific. Therefore, 
it was suggested that Lau-TRH rapidly bound to the BBM in the small intestine, where Lau-TRH is converted to TRH, and this released 
TRH is efficiently transported by an oligopeptide transporter which exists in the upper small intestine. 
Keywords: Thyrotropin-releasing hormone; Lauric acid conjugated thyrotropin-releasing hormone; Intestinal absorption; Oligopeptide transporter; 
Carrier-mediated ransport; Absorption enhancer 
1. Introduction 
Thyrotropin-releasing hormone (TRH: L-pyroglutamyl- 
L-histidyl-L-proline amide) is the hypothalamic peptide that 
regulates the synthesis and the secretion of thyrotropin 
from the anterior pituitary gland [1]. TRH has been shown 
to have not only a variety of endocrine activities, but also 
central nervous system-related biological activities. Re- 
cently, TRH has attached much attention as a potential 
drug for the management of various neurologic and neu- 
ropsychiatric disorders including depression, brain injury, 
acute spinal trauma, schizophrenia nd Alzheimer's dis- 
ease [2,3]. Although orally administered TRH has been 
reported to enhance thyroid stimulating hormone release in 
man, the absolute bioavailabil ity is very low in man (1 -  
2%), in rats (0.2-1.5%), and in dogs (4-13%) [4]. This 
* Corresponding author. Fax: + 81 75 5954761. 
lOW bioavailability may be attributed to its low lipophilic- 
ity. 
Yokohama et al. reported that TRH was absorbed only 
from the upper region of the small intestine [5]. Based on 
the results of an in vitro everted sac experiment, TRH was 
suggested to be transported by a carrier-mediated mecha- 
nism. Recently, Nicklin et al. [6] and Walter and Kissel [7] 
found that TRH was transported across the Caco-2 mono- 
layers by an active transport mechanism. In contrast, some 
investigators failed to find any direct evidence for the 
carrier-mediated transport of TRH in this system [8]. On 
the other hand, it was suggested that the other peptide 
mimetic compounds such as amino-13-1actam antibiotics 
[9-12,37] and angiotensin-converting enzyme inhibitors 
[13] were transported by a di / tr ipept ide carrier mecha- 
nism, as was the case of TRH. 
In a previous report, in order to improve the intestinal 
absorption of TRH, we have synthesized a novel lipophilic 
derivative of TRH (Lau-TRH: Fig. I) by chemical attach- 
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Fig. 1. Chemical structures of TRH and Lau-TRH. 
ment of lauric acid to N-terminal pyroglutamyl group [14]. 
Lau-TRH retained 64 and 81% of the original central 
nervous system activity and thyrotropin-stimulating hor- 
mone releasing activity, respectively [14]. In rat in situ 
closed intestinal loop experiments, the intestinal absorption 
of TRH was significantly increased by a chemical attach- 
ment of lauric acid [15]. However, the absorption mecha- 
nism of Lau-TRH was unclear. 
In the present study, we examined the transport charac- 
teristics of Lau-TRH across the intestine using an in vitro 
everted sac experiment in rats. In addition, we also investi- 
gated the regional differences of Lau-TRH on the intestinal 
absorption and its degradation characteristics in the brush- 
border membrane and cytosolic fractions of the rat small 
intestine. 
each end of the segment was ligated to silicon tubing with 
silk thread. As a serosal fluid, 0.5 ml of the isotonic 
phosphate buffer containing 10 mM D-glucose (pH 7.4) 
was introduced. The everted sac was placed in the isotonic 
phosphate buffer (pH 6.5) containing 10 mM D-glucose 
with 0.1 mM drug bubbled with 95% O 2 and 5% CO 2 at 
37°C. The whole serosal solution was periodically col- 
lected and immediately replaced by the buffer solution. 
The viability of gut sacs during the test period was 
monitored by measuring the transport of Trypan blue dye. 
There was minimal transport of dye during the incubation. 
For the determination of TRH or Lau-TRH, 100 ~1 of 
the sample solutions were added to 50 ~1 of acetonitrile to 
terminate the reaction. The resulting mixture was cen- 
trifuged at 12 000 rev/min for 5 min. Thirty microlitres of 
the supernatant were injected into HPLC. 
The apparent permeability coefficient (P~pv) of each 
drug was calculated according to the following equation: 
dC V 
Papp =dt C O • A 
where, dC/dt is the change in concentration per unit 
time (txmol/ml/s) ,  V is the volume of the serosal fluid 
(ml), C o is the initial concentration of the mucosal drug 
solution (ixmol/ml) and A is the apparent surface area of 
the intestinal membrane (cm2). The P, pp values were 
calculated using data points up to which sink condition 
seemed to be maintained. 
2. Materials and methods 2.3. Preparation of brush-border membrane 
2.1. Chemicals 
TRH was purchased from Peptide Institute, Inc. (Osaka, 
Japan). Lau-TRH was synthesized as reported previously 
[14]. Glycylglycine (Gly-Gly) and EDTA were purchased 
from Nacalai Tesque, Inc. (Kyoto, Japan). 2,4-Di- 
nitrophenol (2,4-DNP) and sodium caprate was obtained 
from Wako Pure Chemicals, Ltd. (Osaka, Japan). O-n- 
Lauryl-[3-D-maltopyranoside (LM) was from Sigma Chem- 
ical Co. (St. Louis, MO, USA). All other chemicals were 
of the finest grade available without further purification. 
2.2. Transport of TRH and Lau-TRH across the intestine 
The transport characteristics of TRH and Lau-TRH 
across the intestinal mucosal membrane was examined 
using the everted sac in rats [16]. In brief, male Wistar rats 
(Japan SLC, Hamamatsu, Japan) (250-300 g) were fasted 
for about 18 h prior to the experiments but given water ad 
libitum. The rats were anesthesized with sodium pento- 
barbital (i.p., 32 mg/ml)  and sacrificed by exsanguination 
from the inferior vena cava. The small intestine was 
quickly removed and separated by three segments, uch as 
the upper, middle and lower regions at each 5-cm long. 
Each segment was rinsed with saline and everted, and then 
Brush-border membranes were isolated from the upper 
and middle small intestine of male Wistar rats (250-300 g) 
according to the CaC12 precipitation method [17]. All steps 
were performed on ice or at 4°C. The purity of the 
membrane was evaluated according to the enrichment of 
alkaline phosphatase, a marker enzyme for brush-border 
membrane. The specific activity of this enzyme was in- 
creased 10-fold in the final membrane suspension as com- 
pared with the crude homogenate of the intestinal scrap- 
ping. The brush-border membrane was diluted to a protein 
concentration of 2 mg/ml.  The protein concentration i
the brush-border membrane was determined by the method 
of Lowry et al. using bovine serum albumin fraction V as a 
standard [ 18]. 
2.4. Preparation of the cytosolic enzyme solution 
The cytosolic fraction of the intestinal mucosal ho- 
mogenate was prepared according to the method of Ganap- 
athy et al. with a slight modification [19]. The activity of 
lactate dehydrogenase, a maker enzyme of the cytosol, was 
measured by the method of Harauchi and Yoshizaki [20]. 
The activity in the final preparation was about 3-fold 
higher than that in the original homogenate. Moreover, the 
activity of alkaline phosphatase, a maker enzyme of 
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brush-border membrane, decreased and was about 80 times 
as low as that in the crude homogenate. The cytosolic 
fraction was diluted with the experimental buffer solution 
to give a protein concentration of 2 mg/ml.  Hence, the 
contamination of brush-border membrane was minimal. 
2.5. Preparation of the intestinal luminal fluid 
The small intestinal fluid was collected from the rat 
according to the method of our previous report [21]. Three 
male Wistar rats, weighing 250-300 g, were anesthetized 
with an i.p. injection of sodium pentobarbital (45 mg/kg). 
After the injection of 10 ml of distilled water into the 
small intestine, cannulated with silicon tubing (3 mm 
i.d. × 5 mm o.d.) at the proximal duodenum and the ileoce- 
cal junction, rats were left for 5 rain and the content was 
washed out by infusing 5 ml of 0.15 M NaCI and the 
eluate was collected. This eluate was extracted five times 
with two-fold volumes of methylene chloride to remove 
lipids that may interfere with the analysis of TRH and 
Lau-TRH by HPLC. This extract was diluted with 0.15 M 
NaC1 to yield a protein concentration of 2 mg/ml  and 
used the small intestinal fluid. 
2.6. Degradation of TRH and Lau-TRH in the brush-border 
membrane and the CVtosol fractions 
2.7. Binding of TRH and Lau-TRH binding to the brush- 
border membrane 
Binding properties of TRH and Lau-TRH to the brush- 
border membrane were evaluated according to the method 
of Saitoh et al. with a slight modification [36]. One 
hundred microlitres of drug solution (0.2 mM) was added 
to 100 ~1 of membrane suspension (2 mg protein/ml) at 
4°C for 30 min. The resulting mixture was centrifuged at 
1200 rev/min at 4°C for 20 rain and 50 I, zl of the 
superuatant fluid was injected into the HPLC. 
2.8. HPLC conditions 
TRH and Lau-TRH were assayed by a gradient HPLC 
system (Hitachi L-6200, Hitachi, Tokyo, Japan) and a data 
processor (Hitachi AS-400 Intelligent Autosampler) using 
a Cl~-column (4.6 × 150 mm) of YMC-pack Protein-RP. 
The mobile phase was a mixture of 0.1% trifluoroacetic 
acid (mobile phase A) and acetonitrile (mobile phase B). 
The gradient system was programmed by linearly increas- 
ing the proportion of mobile phase B from 0 to 70% within 
30 min. The gradient mobile phase was run at a flow rate 
0.8 ml/min. The UV detector was set at 210 nm. 
2.9. Statistical analysis 
The stability of TRH and Lau-TRH in the brush-border 
membrane and the cytosol fractions was examined by 
incubating 200 i~1 of a given concentration of the brush- 
border membrane (2 mg protein/ml) or the cytosol (2 
mg/ml),  which was preincubated at37°C for 15 min, with 
200 ~1 of 0.2 mM TRH or Lau-TRH. At an appropriate 
time, 50 ill was withdrawn from the incubation mixture, to 
which was added 100 Ixl of acetonitrile, to remove tissue 
proteins, thereby terminating the reaction. The resulting 
mixture was centrifuged for 10 rain to remove precipitated 
protein. Thirty microlitres of the supernatant were injected 
into the HPLC. 
Results are expressed as the mean + S.E. Statistical data 
analyses were assessed using the Student's t-test with 
P < 0.05 as the minimal evel of significance. 
3. Results 
3.1. Transport of TRH and Lau-TRH across the intestine 
The penetrated amounts of TRH through the upper 
small intestine were significantly increased by the intro- 
duction of lauric acid into TRH molecule (Fig. 2). AI- 
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Fig. 2. Regional differences in the intestinal transport of (a) TRH and (b) Lau-TRH across the rat everted intestine. The transport characteristics of TRH 
and Lau-TRH across the intestinal mucosal membrane were examined using the everted sac in rats [16]. As a serosal fluid, 0.5 ml of the isotonic phosphate 
buffer containing 10 mM D-glucose (pH 7.4) was introduced. The everted sac (5 cm long) was placed in the isotonic phosphate buffer (pH 6.5) containing 
10 mM D-glucose with 0.1 mM drug bubbled with 95% 02 and 5% CO 2 at 37°C. The whole serosal solution was periodically collected and immediately 
replaced by the buffer solution. These samples were assayed by the HPLC. Results are expressed as the mean _+ S.E. of three experiments. Keys: upper 
small intestine (• ) ;  middle small intestine (£>); lower small intestine (v) ;  large intestine ([]). 
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Table 1 
Regional differences in apparent permeability coefficients of TRH and Lau-TRH across the various intestinal membrane of rat everted sacs 
Papp ( × 10-6 cm/s)  TRH P vs. upper egion Papp ( × 10-6 cm/s)  Lau-TRH P vs. upper egion P vs. TRH 
Small intestine 
Upper region 9.22 + 0.59 24.4 + 4.40 < 0.05 
Middle region 6.42 + 0.30 < 0.02 4.50 + 0.22 < 0.02 < 0.05 
Lower region 5.07 + 0.79 < 0.05 6.13 + 2.25 < 0.02 n.s. 
Large intestine 4.94 + 0.22 < 0.01 3.84 + 0.13 < 0.01 < 0.05 
The everted sac was placed in the isotonic phosphate buffer (pH 6.5) containing 10 mM D-glucose with 0.1 mM TRH or Lau-TRH bubbled with 95% O 2 
and 5% CO 2 at 37°C. The whole serosal solution was periodically collected and immediately replaced by the buffer solution. For the determination f TRH 
or Lau-TRH, 100 I~1 of the sample solutions were added to 50 p~l of acetonitrile to terminate the reaction. These samples were analyzed by the HPLC. 
The apparent permeability coefficient (Papp) of each drug was calculated according to the following equation: 
dt V 
J~app = ~ " CO . A 
where, dC/dt  is the change in concentration per unit time (~zmol/ml/s), V is the volume of the serosal fluid (ml), C o is the initial concentration f the 
mucosal drug solution (~mol/ml) and A is the apparent surface area of the intestinal membrane (cm2). The Papp value was calculated using data points 
up to which sink condition seemed to be maintained. Results are expressed as the mean _+ S.E. of three experiments. Statistical differences were calculated 
by Student's t-test. 
Table 2 
Effects of metabolic inhibitor, dipeptide, low temperature and polarity on the upper small intestinal transport of TRH and Lau-TRH in the rat everted sacs 
Condition Papp (X 10 -6 cm/s)  TRH P vs. control Pdpp ( × 10- 6 cm/s)  Lau-TRH P vs. control 
Control 9.22 + 0.59 24.4 + 4.40 
Non-everted 4.66 _ 0.05 < 0.01 1.36 ___ 0.17 < 0.01 
25°C 6.66 + 0.66 < 0.02 4.95 + 0.94 < 0.05 
10 mM Gly-Gly 6.65 + 0.34 < 0.01 2.33 + 0.16 < 0.02 
0.25 mM 2,4-DNP 3.89 + 0.14 < 0.01 2.30 + 0.17 < 0.001 
The evened sac was placed in the isotonic phosphate buffer (pH 6.5) containing 10 mM D-glucose with 0.1 mM TRH or Lau-TRH bubbled with 95% 02 
and 5% CO 2 under various conditions. The whole serosal solution was periodically collected and immediately replaced by the buffer solution. For the 
determination of TRH or Lau-TRH, 100 I~1 of the sample solutions were added to 50 Izl of acetonitrile to terminate the reaction. These samples were 
analyzed by the HPLC. The apparent permeability coefficient (Papp) under various conditions was calculated by a similar equation to Table 1. Results are 
expressed as the mean _+ S.E. of three experiments. Statistical differences were calculated by Student's t-test. 
though Lau-TRH was very stable in the experimental 
solution, Lau-TRH was enzymatically converted to the 
native TRH in the intestinal mucosal surface and it ap- 
peared as a native TRH form in the serosal side (data not 
shown). Fig. 2 shows the regional differences in the in- 
testinal transport of TRH and Lau-TRH across the rat 
everted intestine. Table 1 shows the apparent permeability 
coefficients of TRH and Lau-TRH across various intestinal 
regions in rat everted sacs. The absorption of both com- 
pounds from the upper small intestinal region were signifi- 
cantly higher than that of other regions. However, no 
significant difference was observed for TRH or Lau-TRH 
transport across the middle and lower small intestine, and 
the large intestine. 
o 
80 E 250 
~ 200 
z 60 
• 'n >= 15o 
< o 100 
20 
~ so 
0 -~ 0 
o 
0 
0 30 60 90 120 
Time (rnin) 
--'2 
30 60 90 120 
Time (min) 
Fig. 3. Effect of various conditions on the transport of TRH (a) and Lau-TRH (b) across the rat upper small intestine. Experimental system was similar to 
Fig. 2. In certain experiments, 10 mM glycylglycine (Gly-Gly) or 0.25 mM 2,4-dinitrophenol (2,4-DNP) were added to the mucosal fluid. Results are 
expressed as the mean + S.E. of three experiments. Keys: control (O); non-everted intestine ([]); 25°C (v) ;  10 mM Gly-Gly (©); 0.25 mM 2,4-DNP 
(i,). 
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3.2. Contribution of carrier-mediated mechanisms to the 
small intestinal absorption of TRH and Lau-TRH 
0 5 10 15 20 25 30 
In an attempt o clarify the transport mechanisms of 
TRH and Lau-TRH across the upper small intestine, we 
examined the effects of metabolic inhibitor, dipeptide, low 
temperature and polarity (directional difference) on their 
upper small intestinal absorption. Fig. 3 shows the trans- 
port profiles of TRH and Lau-TRH across the upper small 
intestine under various conditions. The mucosal-to-serosal 
flux of both compounds was significantly faster than the 
serosal-to-mucosal flux in the upper small intestine. Simi- 
lar results were observed in the presence of dipeptide 
(Gly-Gly) and metabolic inhibitor (2,4-DNP), and under 
the low temperature condition (Table 2). In particular, the 
inhibitory effects of Lau-TRH transport under these condi- 
tions were more predominant than those of TRH. These 
results suggest hat Lau-TRH is also transported across the 
upper small intestine via an oligopeptide transporter by a 
carrier-mediated process as well as TRH. 
3.3. Effect of lipophilic modification and~or the use of 
absorption enhancers on improc, ing TRH transport across 
the intestinal membrane 
We compared the permeation enhancing efficacy by 
lipophilic modification of TRH with those by various 
absorption enhancers (Fig. 4). In the upper small intestinal 
region, all the absorption enhancers tested in this experi- 
ment failed to enhance transport of TRH across the intesti- 
nal membrane, while, in the large intestine, a marked 
increase in its /t)ap values was observed by the addition of 
these absorption enhancers. On the other hand, lipophilic 
modification enhanced the transport of TRH across the 
upper small intestine. However, in the middle small intes- 
tine and large intestine, no enhancing effect was observed 
in the permeation of TRH by lipophilic modification with 
laurie acid. 
3.4. StabiliO, experiments 
In order to examine the degradation properties of Lau- 
TRH on the brush-border membrane in the upper small 
intestine, we investigated the stability of Lau-TRH in the 
brush-border membrane fraction. Thirty percent of Lau- 
TRH was gradually converted to TRH up to 60 min (Fig. 
5). The total recovery percentage of Lau-TRH and TRH 
was approx. 100%, and no degradation products were 
observed except for TRH. A similar result was obtained in 
the middle small intestinal region (data not shown). On the 
other hand, Lau-TRH was extremely stable in the cytosolic 
fraction and the intestinal fluid (data not shown). These 
results indicated that Lau-TRH was converted to TRH by 
the brush-border membrane enzymes of the small intestinal 
mucosa and that there is no regional difference in the 
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Fig. 4. Effects of lipophilic modification and/or the use of absorption 
enhancers on improving TRH transport across the intestinal membrane. 
The apparent permeability coefficient (P~..) of each drug was calculated 
~ dC V 
according to the following equation: P~po dt Co'~ where, dC/dt  is 
the change in concentration per unit time ( Ixmol/ml/s),  V is the volume 
of the serosal fluid (ml), C O is the initial concentration of the mucosal 
drug solution (ixmol/ml) and A is the apparent surface area of the 
intestinal membrane (cm 2). Results are expressed as the mean+ S.E. of 
three experiments. Statistical differences were calculated by Student's 
t-test. LM: O-n-lauryl-[3-D-maltopyranoside. 
3.5. Binding characteristics of Lau-TRH to the BBM 
Fig. 6 shows the binding properties of TRH and Lau- 
TRH to the BBM of the upper small intestine. The binding 
amount of Lau-TRH to the BBM was significantly higher 
than that of TRH. In addition, no significant difference in 
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Fig. 5. Degradation profile of Lau-TRH and corresponding appearance of
TRH in the brush-border membrane prepared from the upper small 
intestine in rats. The stability of Lau-TRH in the brush-border membrane 
was examined by incubating 200 txl of a given concentration of the 
brush-border membrane (2 mg protein/ml), which was preincubated at
37°C for 15 min, with 200 Ixl of 0.2 mM Lau-TRH. At an appropriate 
time, 50 ILl was withdrawn from the incubation mixture, to which was 
added 100 Ixl of acetonitrile, to remove tissue proteins, thereby terminat- 
ing the reaction. The resulting mixture was centrifuged for 10 min to 
remove precipitated protein. These samples were assayed by the HPLC. 
Keys: TRH (O); Lau-TRH ( I ) .  
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Fig. 6. Binding of TRH and Lau-TRH to the small intestinal brush border 
membrane. Brush-border membranes were isolated from the upper and 
middle small intestine of male Wistar rats (250-300 g) according to the 
CaCI 2 precipitation method [ 17]. Binding properties of TRH and Lau-TRH 
to the brush-border membrane were evaluated according to the method of 
Saitoh et al. with a slight modification [36]. One hundred microliters of 
drug solution (0.2 mM) was added to 100 Ixl of membrane suspension (2
mg protein/ml) at 4°C for 30 min. Results are expressed as the mean___ 
S.E. of three experiments. Statistical differences were calculated by 
Student's t-test. 
tween the upper and middle small intestinal region. The 
binding amount of Lau-TRH to the upper small intestinal 
BBM was reduced by the addition of excess amount of 
TRH. Thus, it was suggested that Lau-TRH competed with 
TRH in binding to the upper small intestinal BBM. 
4. Discussion 
In our previous studies, we have synthesized lipophilic 
derivatives of various peptides as such as tetragastrin 
[22,23], calcitonin [24] and insulin [25,26] by chemical 
modification with fatty acids. In preceding papers, we have 
reported that these acyl-peptides were more permeable 
across the intestine than the unmodified peptides while 
retaining their biological activities [23,25,26]. However, 
these peptides were absorbed from the intestine by the 
passive transport system because they consist of more than 
4 amino acid residues. Therefore, it was demonstrated that 
the intestinal absorption of these peptides was improved 
due to the increase in their lipophilicity. 
In this study, we found that the transport of Lau-TRH 
across the upper small intestine was much higher than that 
of TRH. This result was partly due to its lipophilicity 
compared with TRH as assessed by HPLC and partition 
coefficient experiment. We previously reported that the 
partition coefficients of Lau-TRH were 1.91 and 2.14 in 
n-octanol/phosphate buffer and CHC13/phosphate buffer, 
respectively, whereas those of TRH were 0.068 and 0.088, 
respectively [14]. In HPLC analysis, the retention time of 
Lau-TRH (21.3 min) was delayed compared with that of 
TRH (8.01 min). One possible mechanism of enhancing 
Lau-TRH transport is by conversion to lauric acid, a 
degradation product by Lau-TRH, which can enhance the 
permeability of TRH in the gut. However, this mechanism 
was unlikely, as even if all lauric acid was released from 
Lau-TRH, the concentration of this fatty acid would be too 
low to display its absorption enhancing properties in the 
gut. 
The transport characteristics of di/tripeptides into the 
intestinal epithelial cells is an active process which is 
mediated by an oligopeptide transporter localized in the 
BBMs. The transport efficacy of TRH across the upper 
small intestine was relatively low as compared with other 
di/tripeptides and some amino-[3-1actam antibiotics. 
Matthews suggested that the lack of C-terminal carboxyl 
groups of di/tripeptide and the presence of an intramolec- 
ular ~-linkage reduced its affinity to the oligopeptide 
transporter [27]. Bai et al. reported the structural require- 
ment of dipeptide to interact with the oligopeptide trans- 
porter using several dipeptide analogs, suggested that the 
hydrophobic interaction between dipeptides and the trans- 
porter was important to improve their transport efficiency 
[28,29]. Therefore, the introduction of lauric acid into the 
N-terminal pyroglutamyl group of TRH might improve its 
low affinity to the oligopeptide transporter and enhanced 
TRH transport across the upper small intestine. 
In a previous report, we studied the absorption charac- 
teristics of [125I]Lau-TRH using an in situ rat closed 
intestinal oop method [15]. The absorption of [~25I]Lau- 
TRH from the small intestine was decreased in the pres- 
ence of 100-fold excess TRH, suggesting that Lau-TRH 
was partly absorbed by a carrier-mediated transport system 
via an oligopeptide transporter. In order to study the 
further transport mechanism of Lau-TRH across the intesti- 
nal membrane, in the present study, we investigated the 
transport characteristics of TRH and Lau-TRH using an in 
vitro everted intestinal sac experiment. In this experimental 
system, Lau-TRH was specifically transported as a form of 
native TRH across the upper small intestine (Fig. 2). In 
addition, its transport was markedly inhibited under vari- 
ous conditions, such as the addition of 0.25 mM 2,4-DNP 
and 10 mM of Gly-Gly, and the low temperature (Fig. 3). 
Therefore, these findings suggest hat chemical modifica- 
tion of TRH with lauric acid enhanced its transport across 
the upper small intestine by a carrier-mediated transport 
system, which are in good agreement with our previous 
report [15]. 
In a preliminary study, we synthesized chemically mod- 
ified phenylalanyl-glycine (Phe-Gly) derivatives with vari- 
ous fatty acids, and their uptake characteristics into the 
brush-border membrane vesicles (BBMVs). In the pres- 
ence of an inwardly H + gradient, the initial uptake of 
Phe-Gly by the BBMVs was enhanced by the covalently 
attachment of fatty acids to N-terminal of Phe-Gly. More- 
over, their uptake was stimulated by the countertransport 
effects of other dipeptides, and was inhibited by other 
dipeptides (unpublished ata). These detailed results will 
be described in a future report. 
The negative effect of absorption enhancers (10 mM 
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conc.) was observed in the upper small intestinal transport 
of TRH (Fig. 4). These results were corresponded to a 
previous report that the intestinal absorption of 5-fluoro- 
uracil, which was absorbed from the small intestine by a 
cartier-mediated mechanism, failed to be enhanced by 
absorption enhancer [30]. On the contrary, the large intesti- 
nal transport of TRH, whose mechanism was a passive 
diffusion, was significantly improved by the absorption 
enhancers uch as EDTA, caprate and O-n-lauryl-13-D- 
maltopyranoside (LM) (Fig. 4). LM, an alkylsaccharide, 
has recently been found to have absorption enhancing 
activity and to exhibit he absorption enhancing effect even 
at considerably ow concentration with low local irritation 
in the gastrointestinal tract [31]. In general, in the case of 
drugs transported by a passive diffusion mechanism, the 
absorption enhancing actions by various absorption en- 
hancers, such as caprate and LM, in the large intestine 
were more predominant than those in the small intestine 
[31]. Therefore, this finding was in good agreement with 
the previous reports [30]. 
We found only TRH but not Lau-TRH in the serosal 
fluid after administration of Lau-TRH into the mucosal 
fluid. Furthermore, Lau-TRH was extremely stable in the 
small intestinal fluid and cytosol, indicating a little suscep- 
tibility of Lau-TRH to serine proteases, such as chy- 
motrypsin and trypsin, and prolylendopeptidase. On the 
other hand, Lau-TRH was gradually converted to TRH in 
the intestinal BBM fraction (Fig. 5). Accordingly, uniden- 
tified enzymes in the BBM may be responsible for the 
degradation of Lau-TRH. 
We demonstrated that the binding affinity of Lau-TRH 
to BBM was significantly higher than that of TRH. In 
addition, no regional difference on its BBM binding was 
observed between the upper and middle small intestinal 
BBM because its binding was nonspecific due to the 
increased lipophilicity of TRH by lipophilic modification 
(Fig. 6). However, the percentage of Lau-TRH binding to 
the upper small intestinal BBM was decreased by the 
addition of excess TRH (Fig. 6). Thus, it was suggested 
that Lau-TRH was partly bound to the oligopeptide trans- 
porter in the upper small intestine. Although the binding 
mechanism of Lau-TRH is unclear, this high binding to the 
intestinal BBM might play a part role on the enhanced 
transport across the upper small intestine. 
Recently, a cDNA encoding an oligopeptide transporter 
(PepT1) was isolated from the rabbit [32], rat [33] and 
human [34,35] small intestine. Thus, the use of this expres- 
sion system would give further detailed findings for the 
carrier-mediated transport of TRH and its analogs and/or 
prodrugs by the oligopeptide transporter. 
In conclusion, the above results uggested that Lau-TRH 
is highly transported from the upper small intestine by a 
carrier-mediated transport system via an oligopeptide 
transporter and the high affinity of the lipophilic peptide to 
lipid components of BBM might be one of the critical 
factors for the first step of the carrier-mediated transport. 
Furthermore, the acylation might improve the transport of 
various type of peptides and proteins which are transported 
by not only a passive diffusion but also a carrier-mediated 
mechanism. 
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